Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355901 · ClinicalTrials.gov registry record
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
A clinical trial, sponsored by PDL BioPharma.
- Terminated
- Registry status
- 300
- Enrollment target
NCT00355901: Clinical Trial study, sponsored by PDL BioPharma.
NCT00355901 is a clinical trial that was terminated before completion, run by PDL BioPharma. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00355901 was terminated before completion, sponsored by PDL BioPharma.
- TERMINATED
- Registry status
- 300 participants
- Enrollment target
Study Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Interventions
- DRUG Visilizumab (Nuvion®; HuM291)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-11 |
Why NCT00355901 stopped before completion
NCT00355901 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Visilizumab (Nuvion®; HuM291) is the first listed.
NCT00355901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00355901 about?
NCT00355901 is a clinical study titled "An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis". To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
What is the current status of trial NCT00355901?
This trial is currently terminated. The enrollment target is 300 participants. The study started on 2006-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00355901?
The interventions under investigation include: Visilizumab (Nuvion®; HuM291) (DRUG).
Who is sponsoring clinical trial NCT00355901?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia